Targeting Multiple Indications Such as Solid Tumors and Metabolic Diseases Simultaneously
Dispersing Risks from Design to Launch Amid Rising R&D Costs

Domestic pharmaceutical and biotech companies are accelerating their adoption of the “indication diversification” strategy, targeting multiple diseases with a single drug candidate from the early stages of new drug development. This trend is spreading across the industry as a way to disperse the risk of clinical failure for a single indication from the initial design phase and to enhance the value of assets in global licensing deals, particularly as research and development (R&D) costs are structurally soaring.


One New Drug Targets Multiple Diseases... Pharma and Biotech Accelerate "Indication Diversification" View original image

According to the industry on June 16, Celltrion recently announced interim study results for its next-generation multi-antibody new drug, CT-P72/ABP-102, confirming its potential for a wide range of indication expansion as a HER2-overexpressing solid tumor treatment. This substance is an immuno-oncology drug that Celltrion is co-developing with US-based biotech company Abpro Holdings. It is a T cell engager (TCE) therapy that connects cancer cells expressing the HER2 protein to T cells. By leveraging the fact that the single target HER2 is commonly expressed in multiple cancer types, the pipeline was designed from the outset to target solid tumors overall, rather than a single disease. In fact, the strategy’s validity was demonstrated by confirming excellent anticancer efficacy not only in animal models of gastric cancer with acquired resistance to existing therapies but also in multiple cancer types such as bladder, biliary tract, and breast cancers. The company received FDA approval for phase 1 clinical trials in December last year and is currently in the patient screening phase. Celltrion plans to apply for FDA fast track designation within this year, aiming to develop a best-in-class new drug that overcomes resistance and tolerability issues associated with existing HER2 therapies.


Onconic Therapeutics is simultaneously conducting phase 2 clinical trials for four indications—pancreatic, ovarian, endometrial, and gastric cancers—using its next-generation dual-mechanism anticancer drug candidate, Nesuparib. The core strategy is to design the pipeline from the beginning to target multiple cancer types, based on the dual mechanism of inhibiting both PARP (poly ADP ribose polymerase) and tankyrase proteins. Last month at the American Society of Clinical Oncology (ASCO), the company presented phase 1b data for metastatic pancreatic cancer, revealing cases in which some patients maintained complete remission (CR) for more than 40 months. The company also noted an increase in partnership meeting requests from overseas pharmaceutical firms. There is an assessment that a pipeline structure that considers multiple indications from the early stages is serving as a real competitive advantage in global deal negotiations.


JW Pharmaceutical is also simultaneously targeting four indications—obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), and obstructive sleep apnea (OSA)—with Bofanglutide, a GLP-1 receptor agonist introduced from China's Gan & Lee Pharmaceuticals. The fact that the contract milestones explicitly include the development, approval, and sale of these four indications suggests a strategic approach aimed at a comprehensive metabolic disease portfolio, rather than a single disease.


The drive among pharmaceutical and biotech companies to diversify indications from the early stages is closely tied to the structurally rising R&D costs. According to market research firm EvaluatePharma, global pharmaceutical R&D investment is expected to increase from 306 billion dollars in 2023 to 377 billion dollars in 2028—a rise of more than 23% in five years. While new drug development typically takes 10 to 15 years on average, the clinical success rate hovers around just 10%. If a company focuses on a single indication and the clinical trial fails, the value of the asset, into which significant costs were invested, essentially disappears. By constructing pipelines for multiple indications from the design phase, companies can utilize late-stage clinical data for additional indications and preserve asset value even if they fail in a specific disease area.



However, some point out that an indication diversification strategy does not guarantee success. Clinical data requirements and regulatory standards vary by disease, and new safety issues may arise during additional clinical trials, necessitating a cautious approach. An industry official commented, “Simply targeting more indications isn’t necessarily better. If you don’t initially select diseases with clear mechanistic links, clinical resources can become scattered and development speed may actually slow down.” The official added, “The essence of competition lies not just in success for individual diseases, but in how quickly and flexibly a single asset can be structured for expansion and ultimately connected to deals.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing